AMENDMENTS TO THE CLAIMS:

The following listing of claims will replace all prior versions, and listings, of claims in the captioned Application:

LISTING OF CLAIMS:

Claim 1 (currently amended) A pharmaceutical kit for [the] treatment of retinitis pigmentosis [containing] which comprises the enzymes glutathione peroxidase (Enzyme A), prolidase (Enzyme B), glucose-6-phosphate dehydrogenase (Enzyme C) and, optionally, aldose reductase (Enzyme D) in aliquot parts and interactive quantities appropriate for administering:

a) Enzyme A at a concentration generally within a range of 0.03 U.I. and 0.05 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration generally within a range of 5 U.I. and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration generally within a range of 7 U.I. and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye[.]; and

d) Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration generally within a range of [5] 7 U.I. and [7] 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.

Claim 2 (currently amended) The kit set forth in claim 1, wherein the concentration of Enzyme A is about 0.04 U.I. in approximately 0.4 ml of physiological solution, the concentration of Enzyme B is about 6.67 U.I. in approximately 0.4 ml of physiological solution and the concentration of Enzyme C is about 8 U.I. in around 0.4 ml of physiological solution, the concentration of optional Enzyme D being equal to about 8 U.I. in approximately 0.4 ml of physiological solution.

Claim 3 (currently amended) [A] The kit set forth in claim 1, wherein the kit further comprises the enzymes in lyophili[s]zed form, in quantities sufficient for at least one series of administrations of from a) to c) and, optionally, also d), subdivided into

aliquot parts containing, for each enzyme, a selected quantity of enzyme sufficient for the constitution of the aliquot parts.

Claim 4 (currently amended) A kit set forth in claim 1, wherein the kit further comprises the enzymes in lyophili[s]zed form subdivided into one or more aliquot parts, each containing from about 0.04 U.I. to about 0.72 U.I. of Enzyme A, from about 0.67 U.I. to around 120 U.I. of Enzyme B, from approximately 8 U.I. to about 144 U.I. of Enzyme C and, optionally, from around 8 U.I. to about 144 U.I. of Enzyme D, and, optionally, three or more aliquot parts of physiological solution generally within a range of 0.4 ml and 7.2 ml each.

Claim 5 (currently amended) A method of producing a pharmaceutical kit [Use of] which includes the enzymes glutathione peroxidase (Enzyme A), prolidase (Enzyme B), glucose-6-phosphate dehydrogenase (Enzyme C) and, optionally, aldose reductase (Enzyme D) ~~for the preparation of a pharmaceutical composition in kit form~~ for treatment of retinitis pigmentosis by injection into [the] a patient's retrobulbar tissue, the [kit containing] method comprising the steps of providing the enzymes in aliquot parts and in interactive quantities appropriate for administering:

a) Enzyme A at a concentration generally within a range of 0.03 U.I. and 0.05 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration generally within a range of 5 U.I. and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration generally within a range of 7 U.I. and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye[.]; and

d) Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration generally within a range of [5] 7 U.I. and [7] 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.

Claim 6 (currently amended) [Use of the enzymes] The method set forth in claim 5, wherein concentration of Enzyme A is about 0.04 U.I. in approximately 0.4 ml of physiological solution, the concentration of Enzyme B is about 6.67 U.I. in around 0.4 ml of physiological solution and the concentration of Enzyme C is approximately 8 U.I. in about 0.4 ml of physiological solution, the concentration of optional Enzyme D being equal to about 8 U.I. in about 0.4 ml of phisiological solution.

Claim 7 (currently amended) [Use of the enzymes] The method set forth in claim 5, wherein the kit further comprises the enzymes in lyophili[s]zed form, in quantities sufficient for at least one series of administrations of from a) to c) and, optionally, also d), subdivided into aliquot parts [containing] including, for each enzyme, a quantity of enzyme sufficient for the constitution of the aliquot parts.

Claim 8 (currently amended) [Use of the enzymes] The method set forth in claim 5, wherein the kit further comprises the enzymes in lyophili[s]zed form subdivided into one or more aliquot parts, each [containing] having generally within a range of 0.04 U.I. and 0.72 U.I. of Enzyme A, from about 0.67 U.I. to about 120 U.I. of Enzyme B, from about 8 U.I. to about 144 U.I. of Enzyme C and, optionally, from about 8 U.I. to about 144 U.I. of Enzyme D, and, optionally, three or more aliquot parts of physiological solution generally within a range of 0.4 ml and 7.2 ml each.

Claim 9 (cancelled).

Claim 10 (cancelled).